This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Clinicians examined a patient receiving interferon alpha therapy for hepatitis C virus (HCV) infection who was experiencing thyroid dysfunction and concluded it was likely there had been a change in the nature of the antibodies being produced.
The case report was published in the Journal of Medical Case Reports and was written by Gurmit Gill of the Department of Endocrinology and Diabetes at New Cross Hospital in the UK and colleagues.
The authors say, “Clinical thyroid disease is seen in nearly 15% of patients receiving interferon alpha for hepatitis C virus infection.” The patient described in the case report is a 29-year-old female with both type 1 diabetes and HCV. During a planned 24-week course of interferon alpha therapy, at week 17, she developed hyperthyroidism.
This case “emphasizes the need to assess the risk of development of thyroid dysfunction prior to commencement of interferon alpha in patients with HCV infection and to monitor such patients closely clinically and biochemically.” They also stress the need for thorough investigation into the reasons for thyroid dysfunction, adding “an unexpected pattern of thyroid dysfunction is occasionally encountered, as in our patient.”
– See more at: http://www.hcplive.com/medical-news/hep-c-concerns-about-thyroid-disease-and-interferon-treatment-noted#sthash.I1r0BHkQ.dpuf